-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
The Goldman Sachs Group Begins Coverage on LumiraDx (NASDAQ:LMDX)
The Goldman Sachs Group Begins Coverage on LumiraDx (NASDAQ:LMDX)
The Goldman Sachs Group initiated coverage on shares of LumiraDx (NASDAQ:LMDX – Get Rating) in a research report report published on Monday, The Fly reports. The brokerage issued a neutral rating on the stock.
Separately, Raymond James cut their target price on shares of LumiraDx from $4.00 to $3.50 and set an outperform rating on the stock in a research note on Friday, November 11th.
Get LumiraDx alerts:LumiraDx Price Performance
Shares of LMDX opened at $0.94 on Monday. LumiraDx has a fifty-two week low of $0.77 and a fifty-two week high of $10.42. The firm's 50 day moving average price is $1.09 and its 200 day moving average price is $1.63. The company has a market cap of $42.46 million, a P/E ratio of -0.66 and a beta of 1.05. The company has a quick ratio of 1.63, a current ratio of 2.91 and a debt-to-equity ratio of 20.12.
Institutional Investors Weigh In On LumiraDx
A number of large investors have recently modified their holdings of the company. Balyasny Asset Management LLC increased its position in shares of LumiraDx by 36,072.9% in the 3rd quarter. Balyasny Asset Management LLC now owns 3,771,385 shares of the company's stock valued at $3,847,000 after purchasing an additional 3,760,959 shares during the last quarter. Pathstone Family Office LLC purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $47,000. Bill & Melinda Gates Foundation purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $14,600,000. Citadel Advisors LLC purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $39,000. Finally, Seven Grand Managers LLC purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $191,000.About LumiraDx
(Get Rating)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
Further Reading
- Get a free copy of the StockNews.com research report on LumiraDx (LMDX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.
The Goldman Sachs Group initiated coverage on shares of LumiraDx (NASDAQ:LMDX – Get Rating) in a research report report published on Monday, The Fly reports. The brokerage issued a neutral rating on the stock.
据The Fly报道,高盛在周一发布的一份研究报告中首次对LumiraDx(纳斯达克代码:lmdx-Get Rating)的股票进行了报道。该券商对该股的评级为中性。
Separately, Raymond James cut their target price on shares of LumiraDx from $4.00 to $3.50 and set an outperform rating on the stock in a research note on Friday, November 11th.
另外,雷蒙德·詹姆斯在11月11日星期五的一份研究报告中将LumiraDx的目标价从4.00美元下调至3.50美元,并对该股设定了表现优于大盘的评级。
LumiraDx Price Performance
LumiraDx性价比
Shares of LMDX opened at $0.94 on Monday. LumiraDx has a fifty-two week low of $0.77 and a fifty-two week high of $10.42. The firm's 50 day moving average price is $1.09 and its 200 day moving average price is $1.63. The company has a market cap of $42.46 million, a P/E ratio of -0.66 and a beta of 1.05. The company has a quick ratio of 1.63, a current ratio of 2.91 and a debt-to-equity ratio of 20.12.
周一,LMDX的股价开盘报0.94美元。LumiraDx的52周低点为0.77美元,52周高位为10.42美元。该公司的50日移动均线价格为1.09美元,200日移动均线价格为1.63美元。该公司市值为4246万美元,市盈率为-0.66,贝塔系数为1.05。该公司的速动比率为1.63,流动比率为2.91,债务权益比为20.12。
Institutional Investors Weigh In On LumiraDx
机构投资者参与LumiraDx
About LumiraDx
关于LumiraDx
(Get Rating)
(获取评级)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
LumiraDx有限公司是一家医疗诊断公司。该公司专注于通过向医疗保健提供者提供关键诊断信息来转变基于社区的医疗保健。它制造和销售一种诊断平台,该平台支持各种测试,在护理点具有实验室可比的性能。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on LumiraDx (LMDX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- 免费获取StockNews.com在LumiraDx(LMDX)上的研究报告
- 你买下Palantir的决定可能只是个时间问题
- 卡特彼勒和迪尔准备在2023年重整旗鼓吗?
- 马伦汽车公司在i-Go登陆欧洲之际受到震动
- 2023年,太阳会照耀这3只大盘太阳能股吗?
- Lucid Motors面临的现实可能会给看涨的看法蒙上阴影
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.
接收LumiraDx日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对LumiraDx和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧